Compare iShares MSCI Taiwan ETF (EWT) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Taiwan ETF vs Merck & Co., Inc. — how do they compare? iShares MSCI Taiwan ETF trades at $114.85 (market cap $12.74B), while Merck & Co., Inc. trades at $142.44 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 27.6× iShares MSCI Taiwan ETF's market cap, and Merck & Co., Inc. pays a 2.39% dividend while iShares MSCI Taiwan ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Taiwan ETF for 52 Days and Merck & Co., Inc. for 98 Days on average.
| EWT | MRK | |
|---|---|---|
Market Cap | $12.74B | $351.28B |
Volume | 8,470,920 | 7,969,665 |
Sector | Broad Market / Factor | Health |
52-Week High | $118.00 | $156.43 |
52-Week Low | $60.03 | $82.49 |
Typical Hold Time | 52 Days | 98 Days |
Enterprise Value | — | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWT, the iShares MSCI Taiwan ETF, trades at $116.24, down 1.16% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF is heavily concentrated in Taiwan's semiconductor sector, particularly TSMC, benefiting from AI-driven demand. Recent news highlights strong institutional interest and substantial Taiwanese corporate investments in U.S. AI infrastructure, though geopolitical tensions with China present ongoing risks.
The outlook for EWT is positive due to Taiwan's pivotal role in AI and semiconductor supply chains, supported by robust capital expenditure plans from key holdings. However, elevated geopolitical risks and sector concentration require careful monitoring. Upside potential hinges on sustained AI demand, while downside risks include cross-strait tensions and global tech volatility.
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Taiwan ETF
EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.
Read more on EWT →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
